
| Pair Name | Nimbolide, Docetaxel | ||
| Phytochemical Name | Nimbolide (PubChem CID: 12313376 ) | ||
| Anticancer drug Name | Docetaxel (PubChem CID: 148124 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Nimbolide, Docetaxel | |||
| Disease Info | [ICD-11: 2C82.0] | Prostate cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Activity | NFKB1 | hsa4790 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | XIAP | hsa331 | |
| In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
| PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 | |
| PC-3 D12 | Prostate carcinoma | Homo sapiens (Human) | CVCL_4Y40 | |
| In Vivo Model | 8-week-old male SCID mice were orthotopically implanted with LNCaP-Luc or PC-3-Luc cells to induce tumors. | |||
| Result | The combination of NL and DTX significantly reduced the DNA binding ability of NF-κB in both cell types. NL significantly enhanced the antitumor effect of DTX and reduced metastases in orthotopic models of prostate cancer. NL abolishes DTX-induced-NF-κB activation to counteract cell proliferation, tumor growth, and metastasis in the prostate cancer models. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Nimbolide enhances the antitumor effect of docetaxel via abrogation of the NF-κB signaling pathway in prostate cancer preclinical models. Biochim Biophys Acta Mol Cell Res. 2022 Dec;1869(12):119344. doi: 10.1016/j.bbamcr.2022.119344. | Click |